Instead, they assign a Beyond-Use Date (BUD) based on United States Pharmacopeia (USP) guidelines and any stability data they have generated
Over 84 weeks, the average weight loss was 25.5% with tirzepatide compared with 23.0% with CagriSema
The participants had underlying health conditions, including diabetes, non-alcoholic steatohepatitis, knee osteoarthritis, or were undergoing hemo-dialysis
Zhang L, Johnson B, Zhao S, Xie Z, Andreeff M , Claxton DF
They differ from GLP-1s in that they target not only the GLP-1 hormone but also the GIP (glucose-dependent insulinotropic polypeptide) hormone, which helps to lower A1C, or blood glucose levels
Avoid heat above 40C 4.00 - 10.00 Soluble in Water, Dispersible in water, Soluble in DMSO (Dimethyl Sulfoxide) Serum -